Scientists have developed a CRISPR gene-editing technique that can potentially correct a majority of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD) by making a single cut at strategic points along the patient’s DNA, according to a study from UT Southwestern Medical Center.
The method, successfully tested in heart muscle cells from patients, offers an efficient alternative to the daunting task of developing an individualized molecular treatment for each gene mutation that causes DMD. It also opens up possible new treatment approaches for other diseases that have thus far required more intrusive methods to correct single-gene mutations.
Scientists say the new strategy enhances the accuracy for surgical-like editing of the human genome, correcting mistakes in the DNA sequence that cause devastating diseases like DMD, a deadly condition caused by defects in the dystrophin gene. Normally, the dystrophin protein helps strengthen muscle fibers.
“This is a significant step,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “We’re hopeful this technique will eventually alleviate pain and suffering, perhaps even save the lives, of DMD patients who have a wide range of mutations and, unfortunately, have had no other treatment options to eliminate the underlying cause of the disease.”
A study published in Science Advances documents the success of a new CRISPR gene-editing technique designed to treat Duchenne muscular dystrophy (DMD).
- The new strategy can potentially correct a majority of the 3,000 types of mutations that cause DMD.
- It requires only a single cut at strategic points along the patient’s DNA and is less intrusive than traditional gene-editing methods.
- 12 guide RNAs developed to find mutation “hotspots” along the dystrophin gene helped rescue cardiac function to near-normal levels in human heart muscle tissue.
- The work builds upon previous CRISPR research from Dr. Eric Olson, including studies from 2014, 2016 and 2017.
The research, the cover story of this month’s Science Advances, builds upon previous studies from Dr. Olson in which CRISPR-Cas9 corrected a single gene mutation that caused DMD in mice. The new study demonstrates how a wide range of mutations can be corrected in human cells by eliminating abnormal splice sites in the genomic DNA.
These splice sites instruct the genetic machinery to build abnormal dystrophin molecules, but once the gene is successfully edited it expresses a much-improved dystrophin protein product, enhancing the function of the muscle tissue.
“In fact, we found that correcting less than half of the cardiomyocytes (heart muscle cells) was enough to rescue cardiac function to near-normal levels in human-engineered heart tissue,” said Dr. Chengzu Long, lead author of the study and Assistant Professor of Medicine at New York University Langone Health.
DMD is a rare disease affecting primarily boys and is caused by defects in the gene that makes the dystrophin protein. These defects – which could affect any of the 79 exons that comprise the gene – lead to degeneration of skeletal and heart muscles, forcing patients into wheelchairs and, due to degeneration of chest wall muscles needed for breathing, eventually onto respirators. Most patients die by age 30. No cure has been developed.
The disease is among many conditions that scientists are hoping to treat through the recently developed CRISPR-Cas9 gene-editing tool, in which an RNA strand guides an enzyme called Cas9 to cut a specific portion of DNA.
Pending federal government approval, it is anticipated that U.S. clinical trials involving CRISPR gene editing will begin this year, starting in blood disorders, as researchers continue studying the best methods to maximize efficiency and reduce the potential for unintended edits to the genome.
Dr. Olson’s lab spent substantial time developing and testing various guide RNAs (ribonucleic acids) that could lead the Cas9 enzyme precisely to 12 designated splice sites and avoid errant edits. These sites were targeted because they are located at “hot spots” along the dystrophin gene where up to 60 percent of the disease-causing mutations occur.
“This is a new concept,” said Dr. Rhonda Bassel-Duby, co-author of the study and Professor of Molecular Biology at UT Southwestern. “Not only did we find a practical way of treating many mutations, we have developed a less disruptive method that skips over defective DNA instead of removing it. The genome is highly structured and you don’t want to remove DNA that could potentially be important.”
The strategy of single-cut editing may be useful for treating other single-gene diseases, Dr. Olson said. However, the genes involved must be able to function if certain exons are removed from the protein recipe.
“Dystrophin is like a big shock absorber; removal of a few coils of the springs is fine. Other proteins may not be so easy,” said Dr. Olson, Co-Director of the Wellstone Muscular Dystrophy Cooperative Research Center, and Professor and Chair of Molecular Biology at UT Southwestern.
Dr. Olson’s lab will continue testing the method to ensure it does not have adverse side effects, in addition to seeking ways to improve the precision of the guide RNAs. In the meantime, the work has spawned a new biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
“This is a major advance,” Dr. Bassel-Duby said. “Many different therapies have been put forward, but this one provides real hope to extend and improve the quality of patients’ lives.”
Some of those patients have already seen firsthand how gene editing can correct defects in their cells. Dr. Jay Schneider, a co-author of the study, recalls the first DMD patient who donated cells to the research effort several years ago.
The patient, already in a wheelchair, visited the lab and watched in amazement as his own muscle cells beat in a culture dish after corrective editing.
“This was an incredibly inspiring moment, not only for this awestruck patient, but for the whole clinical and scientific team,” said Dr. Schneider, Associate Professor of Internal Medicine and Dallas Heart Ball Chair in Cardiac Research at UT Southwestern. “Taking medical problems like DMD from the patient to the lab bench and then back to the patient is the vision, and these new gene-editing technologies are making this vision a reality.”
The Latest on: CRISPR
Cancer cells engineered with CRISPR slay their own kin
on July 11, 2018 at 11:21 am
Using gene editing, scientists have hoodwinked tumor cells into turning against their own kind. Cancer cells circulating in the bloodstream have something of a homing instinct, able to find and return ... […]
CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds
on July 11, 2018 at 11:16 am
s an idea for wiping out cancer, it could have been ripped from the pages of a spy thriller: Take cancer cells that have departed the original tumor and spread elsewhere in the body, genome-edit them ... […]
Here's Why CRISPR Therapeutics AG Fell 14.7% in June
on July 11, 2018 at 9:46 am
Shares of CRISPR Therapeutics (NASDAQ: CRSP) dropped almost 15% last month after Wall Street caught wind of results from two studies suggesting that a certain CRISPR tool may be linked to cancer. The ... […]
CRISPR's growing pains
on July 11, 2018 at 9:26 am
In the six years since its inception, CRISPR gene editing has experienced ups and downs, from giddy excitement over the technology's potential to cure genetic diseases to patent disputes, ethical cons... […]
Researchers discover why CRISPR gene editing sometimes fails
on July 11, 2018 at 8:45 am
A study conducted at the University of Illinois, Chicago has explained for the first time why the CRISPR gene editing tool sometimes fails to work. The study authors also suggest steps that can be tak... […]
Biochemists discover cause of genome editing failures with hyped CRISPR system
on July 11, 2018 at 7:54 am
Researchers are the first to describe why CRISPR gene editing sometimes fails to work, and how the process can be made to be much more efficient. Researchers from the University of Illinois at Chicago ... […]
Cause of CRISPR Failure Identified and Reversed
on July 11, 2018 at 6:50 am
The clustered regularly interspaced short palindromic repeats (CRISPR) system has evolved in bacteria as a form of adaptive immune system, which scientists have customized as a versatile tool for gene ... […]
Researchers reveal why CRISPR gene editing sometimes fails to work
on July 11, 2018 at 3:01 am
Researchers from the University of Illinois at Chicago are the first to describe why CRISPR gene editing sometimes fails to work, and how the process can be made to be much more efficient. CRISPR is a ... […]
Controversial CRISPR “Gene Drives” Tested in Mammals for the First Time
on July 10, 2018 at 12:23 pm
A controversial technology capable of altering the genomes of entire species has been applied to mammals for the first time. In an article posted on the bioRxiv preprint server on 4 July, researchers ... […]
Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far)
on July 10, 2018 at 6:37 am
Shares of the three companies pioneering medical applications of CRISPR gene-editing tools have soared higher through the first half of 2018. That's because, after years of only being able to discuss ... […]
via Google News and Bing News